<DOC>
	<DOCNO>NCT00498173</DOCNO>
	<brief_summary>This study evaluate effectiveness atomoxetine treat child attention deficit hyperactivity disorder symptom associate autistic disorder , Asperger 's syndrome , pervasive developmental disorder , otherwise specify .</brief_summary>
	<brief_title>Effectiveness Atomoxetine Treating ADHD Symptoms Children Adolescents With Autism</brief_title>
	<detailed_description>Autism developmental disorder cause severe pervasive impairment thinking , feeling , language , ability relate others . It usually first diagnose early childhood . Children autism demonstrate repetitive behavior interest deficit social interaction , verbal communication , nonverbal communication . In addition , often unusual response sensory experience , certain sound way object look . Some symptom attention deficit hyperactivity disorder ( ADHD ) , inattention , hyperactivity , impulsivity , also associate autism . Atomoxetine selective norepinephrine reuptake inhibitor use treat ADHD . It work differently , however , stimulant drug may help reduce ADHD symptom child autism . This study evaluate effectiveness atomoxetine treat child ADHD symptom associate autism . Potential participant first attend screen visit , include psychiatric diagnostic interview , practice session swallow pill capsule , physical exam , electrocardiogram ( ECG ) , blood test , assessment pubertal stage . Females childbearing age also undergo urine pregnancy test . In initial double-blind study phase , eligible participant randomly assign receive either atomoxetine placebo 8 week . A baseline visit include several rating scale , observation , interview assess adaptive functioning . These measure procedure use keep track symptom , side effect , behavior could change study . Children assign placebo notice improvement ADHD symptom give opportunity receive atomoxetine end 8 week . Study visit occur week 4 week , every week remainder 8 week . During visit , many baseline questionnaire interview repeat . At Week 8 visit , physical exam , ECG , blood test , baseline questionnaire also repeat . All child respond well atomoxetine may continue take drug additional 10 month . During time , participant report clinic month first 4 month , end 7 month , finally end 10 month . The measure procedures do 8-week phase do 10-month phase study .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Diagnosis autism spectrum disorder ( autistic disorder , Asperger 's syndrome , pervasive developmental disorder , otherwise specify ) . Significant hyperactivity , inattention , impulsivity determine score investigatoradministered ADHD Rating Scale ( ADHDRS ) Home Version least 1.5 standard deviation mean age sex Parent/caregiver 's primary complaint child inattention , hyperactivity , and/or impulsivity ( `` ADHD '' symptom ) Symptoms present 6 month prior study entry Psychotropic drugfree least 2 week prior start study medication . This drugfree period 5 week fluoxetine ( Prozac ) . Weighs le 15 kg ( 33 pound ) Any another psychiatric disorder may require different treatment , include psychotic disorder , major affective disorder , obsessivecompulsive disorder , panic disorder , substancerelated disorder Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) diagnosis Rett 's disorder childhood disintegrative disorder Presence extreme aggression selfinjury Currently take effective psychotropic drug Currently use medication may unsafe take atomoxetine ( e.g. , potent CYP 2D6 inhibitor , intravenous albuterol , monoamine oxidase inhibitor [ MAO ] ) Inability swallow study medication Presence medical condition would make treatment atomoxetine unsafe ( e.g. , unstable hypertension cardiac disease , asthma require frequent treatment albuterol , narrow angle glaucoma , pregnancy , etc . ) Mental age le 18 month Previous adequate trial atomoxetine Previous evidence hypersensitivity allergic reaction atomoxetine Clinically significant abnormality laboratory measure indicate undiagnosed medical condition determine study physician discussion participant 's primary care physician Clinically significant abnormality ECG determine pediatric cardiologist Pregnant Initiation new psychosocial intervention within 90 day prior start study medication . Participants recently significant change psychosocial intervention eligible intervention stable 90 day order avoid confound result study . Stable intervention ( e.g. , speech occupational therapy ) allow continue course study . Minor change ongoing treatment ( e.g. , missed therapy session due holiday/vacation plan break therapy due school holiday ) consider significant .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Autistic Disorder</keyword>
	<keyword>Autism Spectrum Disorder</keyword>
</DOC>